CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report)’s share price crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $0.24 and traded as high as $0.24. CytoDyn shares last traded at $0.21, with a volume of 2,048,823 shares changing hands.
CytoDyn Trading Down 7.9 %
The firm has a market capitalization of $260.04 million, a price-to-earnings ratio of -21.10 and a beta of 1.33. The stock’s 50-day moving average is $0.24 and its 200-day moving average is $0.17.
CytoDyn Company Profile
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Featured Stories
- Five stocks we like better than CytoDyn
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Archer Aviation’s Africa Deal Could Boost ACHR Stock
- Insider Buying Explained: What Investors Need to Know
- Are Short Sellers Wrong About These 3 Semiconductor Stocks?
- How to Profit From Value Investing
- Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
